What are ADC's

Our services

ADC Review
is made possible by:

NCT01363947 / Study DNB4987g (Clinical Trial/ Lifastuzumab Vedotin / Anti-NaPi2b ADC / RG-7599 / DNIB0600A)

Study Title
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer (NCT01363947)

Trial Description
Study DNB4987g is a Phase I, multicenter, open label, dose-escalation study of DNIB0600A (also known as Lifastuzumab Vedotin / Anti-NaPi2b ADC / RG-7599 / DNIB0600A) administered as a single agent by intravenous (IV) infusion to patients with non-squamous NSCLC or non-mucinous, platinum resistant ovarian cancer.

This trial is sponsored by Genentech. [1]

Study Data

  • Condition: Lung Cancer, Ovarian Cancer
  • Interventions:
    • Drugs used in this trial
      • DNIB0600A (Lifastuzumab Vedotin; Anti-NaPi2b ADC; RG-7599; DNIB0600A)
  • Phase: I
  • Estimated Enrollment: 96
  • Start: June 2011
  • Estimated Completion: March 2017
  • Last verified: July 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 10, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar